International Circuit
Emmaus Life Sciences Announces Its Common Stock To Begin Trading
Emmaus Life Sciences, Inc. a leader in sickle cell disease treatment, today announced it is approved to have its common stock trade on the OTCQB marketplace, effective September 26, 2019. The common stock of Emmaus was previously quoted on OTC Link® as OTC Pink.
“Trading on OTCQB is an important next step for Emmaus in moving to a major exchange,” stated Jay Sherwood, Chief Financial Officer of Emmaus. “The OTCQB requires increased reporting standards by its issuers and provides greater transparency and visibility of trade data, news and disclosures to the investment community, as well as offers convenient trading with real-time quotes through more broker dealers. Trading on the OTCQB will afford Emmaus with exposure to a quality tier of investors and the potential to further enhance liquidity for its shareholders.” – BioSpace